UT Health East Texas - North Campus

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both

Retrieved on: 
Monday, December 12, 2022
University, OH, Cincinnati Children's Hospital Medical Center, UT Health East Texas - North Campus, AOM, Norovirus, Security (finance), Government, Hospital, FDA, BWV, University of Texas Health Science Center at San Antonio, Risk, Vaccine, Streptococcus pneumoniae, VLP, Media, Infection, Nov, Malaria, Projection, Water, S&P, Pneumonia, Research, COVID-19, Form, Pharmaceutical industry, Maxim
Key Points: 

    Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress

    Retrieved on: 
    Thursday, December 1, 2022
    COVID-19, Cincinnati Children's Hospital Medical Center, AOM, Vaccine, University of Texas Health Science Center at San Antonio, Hospital, University, Streptococcus pneumoniae, Malaria, S&P, Government, St. Jude Children's Research Hospital, UT Health East Texas - North Campus, Security (finance), OH, Infection, BWV, VLP, Risk, Research, Form, Norovirus, Media, Nov, FDA, Pharmaceutical industry, Chlamydia

    Although our primary targets of this vaccine remain AOM and pneumococcal pneumonia, data from the original publication for this vaccine suggests that BWV-201 may also protect against invasive pneumococcal disease.

    Key Points: 
    • Although our primary targets of this vaccine remain AOM and pneumococcal pneumonia, data from the original publication for this vaccine suggests that BWV-201 may also protect against invasive pneumococcal disease.
    • We look forward to sharing our strategy with all colleagues in attendance and further advancing this program into clinical trials.
    • Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally.
    • Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.

    UT Health San Antonio plans new MS in Imaging Sciences program

    Retrieved on: 
    Monday, November 14, 2022
    Health, SAN, Doctor of Philosophy, SACSCOC, Veteran, UT Health East Texas - North Campus, Texas Department of State Health Services, Anatomy, University of Texas System, Texas Medical Board, University of Texas Health Science Center Department of Radiology, Texas Higher Education Coordinating Board, Radiographer, Master of Science, Baptist Health System School of Health Professions, MS, Student, MBA, RT, Magnetic resonance imaging, Leadership, RVT, Physiology, University, Workforce, Department, University of Texas Health Science Center at San Antonio, Time, Education, Research, Program, Curriculum, Pharmacology, Patient, Certification, COVID-19, Radiography, MRI, American Registry for Diagnostic Medical Sonography, School, Matriculation, CT, Medicine, Medical imaging, Science, MD, Radiology, Society for Imaging Science and Technology

    SAN ANTONIO, November 14, 2022 /PRNewswire-PRWeb/ --The School of Health Professions at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) plans to launch a new Master of Science in Imaging Sciences program to train imaging technologists in radiography, computed tomography (CT) and magnetic resonance imaging (MRI) to address the technologist shortages currently stressing the health care system.

    Key Points: 
    • A new Master of Science in Imaging Sciences program at UT Health San Antonio will be unique as an entry-to-the-profession master's degree program that provides eligibility for three national certifications by the American Registry of Radiologic Technologists.
    • The planned degree program is under the auspices of the School of Health Professions at The University of Texas Health Science Center at San Antonio (UT Health San Antonio).
    • SAN ANTONIO, November 14, 2022 /PRNewswire-PRWeb/ --The School of Health Professions at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) plans to launch a new Master of Science in Imaging Sciences program to train imaging technologists in radiography, computed tomography (CT) and magnetic resonance imaging (MRI) to address the technologist shortages currently stressing the health care system.
    • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver for San Antonio's $42.4 billion health care and biosciences sector, is the largest research university in South Texas with an annual research portfolio of $350 million.

    NORTHSTAR ANESTHESIA ANNOUNCES NEW SERVICES AND A RESIDENCY PROGRAM AT UT HEALTH TYLER

    Retrieved on: 
    Wednesday, August 31, 2022
    Partnership, Patient, University, University of Texas System, Technology, Caregiver, Program, Research, University of Texas Southwestern Medical Center, Anesthesiology, Level 1, UT System, CRNA, Crna, Physician, UT Health East Texas - North Campus, EMS, Education, Hospital, OR, UT, Anesthesia, Ardent Health Services, Ambulance, Health care, Trauma, University of Texas at Austin, Industry, NorthStar, Health, Oil, Medicine

    "I'm very excited to announce that we will now provide anesthesia care at UT Health Tyler and participate in a residency program to improve education for anesthesia providers in the community," said NorthStar CEO Adam Siegel.

    Key Points: 
    • "I'm very excited to announce that we will now provide anesthesia care at UT Health Tyler and participate in a residency program to improve education for anesthesia providers in the community," said NorthStar CEO Adam Siegel.
    • UT Health Tyler, part of Ardent Health Services, is a 432-bed hospital in Tyler, Texas, with over 2,000 employees.
    • "At UT Health Tyler, we prioritize compassionate care that is driven by technology and research," said Dr. Tom Cummins, Chief Medical Officer at UT Health East Texas.
    • UT Health Tyler and NorthStar hope to launch the program in July 2024.

    NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer

    Retrieved on: 
    Monday, August 1, 2022
    Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Diagnosis, U.S. FDA, Â, Ovary, Taxane, Bladder cancer, Safety, Tumor microenvironment, Cystoscopy, Lung, Clinical trial, Method, Urology, SEER, BCG, HIV disease progression rates, University of Texas Health Science Center at San Antonio, Johns Hopkins University, Journal, Technology, Prostate, Cystectomy, Biopsy, Docetaxel, Johns Hopkins School of Medicine, Quality of life, Recurrence, FDA, Blood, Neoplasm, Treatment, View, Worldwide, Toxicity, NMIBC, Maintenance, The New England Journal of Medicine, TURBT, Bacillus, Associate, Private Securities Litigation Reform Act, Pancreas, Risk, UT Health East Texas - North Campus, Patient, NK, Medical imaging, Pharmaceutical industry, Dietary supplement, LLC, MD

    NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of Large Surface Area Microparticle Docetaxel (LSAM-DTX) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) have been published in The Journal of Urology .

    Key Points: 
    • NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of Large Surface Area Microparticle Docetaxel (LSAM-DTX) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) have been published in The Journal of Urology .
    • The research article entitled Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-Muscle Invasive Bladder Cancer presents safety and response data from the multi-site study ( NCT03636256 ).
    • Worldwide, an estimated 573,000 people were diagnosed with bladder cancer in 2020 and 81,000 people will be diagnosed with bladder cancer in the United States in 2022.
    • In this Phase 1/2 clinical trial, LSAM-DTX showed promising signs of preventing disease progression and interesting immunogenic effects with minimal adverse events.

    Foundation for Sarcoidosis Research Launches Groundbreaking Global Rare Disease Initiative

    Retrieved on: 
    Tuesday, June 21, 2022
    University of Mississippi Medical Center, University of Florida College of Medicine-Jacksonville, Medical school, University of Virginia, Stanford University School of Medicine, Man, Hospital, University, Health, Quality of life, Incidence, Royal Oak, Jane, Interview, Florida College, UCLA, Thomas Jefferson University, Alliance, Mount Sinai Medical Center, Program, Emory Healthcare, Education, Chan Zuckerberg Initiative, Beaumont Health, National Jewish Health, UT Health East Texas - North Campus, Patient, Medical University of South Carolina, Multimedia, Rare, McGowan, Woman, FSR, STAR, VCU, Research, Foundation, Inflammation, Inova Health System, Center of excellence, Pharmaceutical industry, Medicine, Sarcoidosis

    CHICAGO, June 21, 2022 /PRNewswire/ -- Foundation for Sarcoidosis Research (FSR)announces the launch of the FSR Global Sarcoidosis Clinic Alliance, a groundbreaking initiative that will have a worldwide impact on advancing sarcoidosis research and improving the lives of those with sarcoidosis through patient and clinician education, engagement, and support.

    Key Points: 
    • CHICAGO, June 21, 2022 /PRNewswire/ -- Foundation for Sarcoidosis Research (FSR)announces the launch of the FSR Global Sarcoidosis Clinic Alliance, a groundbreaking initiative that will have a worldwide impact on advancing sarcoidosis research and improving the lives of those with sarcoidosis through patient and clinician education, engagement, and support.
    • The FSR Global Sarcoidosis Clinic Alliance brings together sarcoidosis clinics and hospitals committed to finding a cure and offering evidence-based, patient-centric care for those living with sarcoidosis.
    • "We are honored to already be collaborating with 22 esteemed founding members of this groundbreaking rare disease initiative which will lead to extraordinary results.
    • Established in 2000, Foundation for Sarcoidosis Research (FSR), is the leading international non-profit organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients through research, education, and support.

    Commissioner Calvert's 2018 University Health Senior Property Tax Freeze Expected to Help Homeowners

    Retrieved on: 
    Tuesday, June 7, 2022
    Leadership, LA Weekly, Tax exemption, Tax, COVID, Calvert, Brooks, University of the Incarnate Word, County, University of the Incarnate Word School of Osteopathic Medicine, College, Commissioner, East Side, Partnership, MAGA, Travel, Commissioners' court, City, University, Osteopathic medicine in the United States, School, Moses Austin, University Health System, Emergency service, Austin American-Statesman, COVID 19, UT Health East Texas - North Campus, SAN, Republican, Health, Life insurance, Health insurance, Hospital

    SAN ANTONIO, June 7, 2022 /PRNewswire/ -- Rising property appraisals and hidden taxes set by a MAGA Republican-controlled Texas Legislator are hurting seniors and working families. Bexar County Commissioner Tommy Calvert plans to increase the senior property tax exemption he created in 2016 from $10,000 to $30,000 per homestead.

    Key Points: 
    • Bexar County Commissioner Tommy Calvert plans to increase the senior property tax exemption he created in 2016 from $10,000 to $30,000 per homestead.
    • County Commissioners will also vote to raise Commissioner Calvert's University Health property tax exemption for seniors to $30,000.
    • In 2018, Commissioner Calvert created and passed the initial $10,000 University Health System tax exemption for seniors after longtime southeast side resident Robert Koening approached him during a Highland Hills Neighborhood Association meeting in 2015 for a senior property tax freeze.
    • Commissioner Calvert has also supported a new University Health hospital near Texas A&M University-San Antonio and created the newly formed Public Health Division within University Health.

    The University of Texas Health Science Center at San Antonio and ADA Science & Research Institute receive $2.4 million NIH grant to study responsible antibiotic use

    Retrieved on: 
    Wednesday, April 27, 2022
    Plaque, Chan Zuckerberg Initiative, Medicine, Inflammation, American Academy, Peri-implantitis, University of Texas Health Science Center at San Antonio, Periodontal disease, Guideline, Patient, Huber loss, Degenerative disease, National Institute, Classification, Education, Cardiovascular disease, ADA, Organization, Food, SAN, Clinical trial, Dentist, University, Dental care, MS, Nursing, Research, American Academy of Periodontology, Dentistry, Doctor of Philosophy, National Dental Examining Board of Canada, National Institute of Dental and Craniofacial Research, National, Periodontology, Diabetes, Breast implant, University of Texas System, NIH, Risk, Population, DDS, Health, National Institutes of Health, UT Health East Texas - North Campus, Disease, School, Pharmaceutical industry, Dental

    SAN ANTONIO, April 27, 2022 /PRNewswire-PRWeb/ --The National Institutes of Health has awarded a four-year, $2.4 million grant to The University of Texas Health Science Center at San Antonio (UT Health San Antonio), which will work in collaboration with the American Dental Association Science & Research Institute (ADASRI) to conduct a clinical trial studying the responsible use of antibiotics in combination with other treatments for periodontal disease, commonly known as gum disease.

    Key Points: 
    • The study, funded by NIH's National Institute of Dental & Craniofacial Research, will be led by principal grant recipient and investigator Georgios Kotsakis, DDS, MS, associate professor of periodontics at the UT Health San Antonio School of Dentistry.
    • For UT Health San Antonio, one of the country's leading health sciences universities and the largest research university in South Texas, the grant builds on its ranking in the top 3% worldwide of all organizations that receive NIH funding.
    • The University of Texas Health Science Center at San Antonio , also referred to as UT Health San Antonio, is one of the country's leading health sciences universities and is the largest research university in South Texas with an annual research portfolio of approximately $350 million.
    • Steven Lee, The University of Texas Health Science Center at San Antonio, 210-450-3823, [email protected]

    WEconnect Recovery and UT Health San Antonio Provide Texans with New Innovative Mobile Recovery Options for Substance Use Disorder Regardless of Insurance Status

    Retrieved on: 
    Friday, April 15, 2022
    Public Policy, Government, Software, General Health, Health, Mental Health, Healthcare Reform, Technology, Mobile, Wireless, Well, CEO, Habit, Prescription, University, PCP, Suds, MAT, Addiction medicine, Psychiatry, University of Texas System, SUD, Technology, Insurance, UT Health East Texas - North Campus, Solution, Physician, University of Texas Health Science Center at San Antonio, Research, Management, Pharmaceutical industry, Health insurance

    WEconnect Health Management today announced it has expanded its relationship with Be Well Texas at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) to make its WEconnect Recovery app available to Texans dealing with substance use disorders (SUD), including the more than 20% of Texans without health insurance.

    Key Points: 
    • WEconnect Health Management today announced it has expanded its relationship with Be Well Texas at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) to make its WEconnect Recovery app available to Texans dealing with substance use disorders (SUD), including the more than 20% of Texans without health insurance.
    • The WEconnect Recovery platform provides a free and premium app and mobile support groups designed to support the people dealing with SUDs and mental health issues.
    • Substance misuse doesnt care where you work, what you do or what insurance you have, said Daniela Luzi Tudor, CEO and co-founder of WEconnect Health Management.
    • WEconnect Health Management is a healthcare technology company focused on solving the biggest public health crisis of our time: substance use disorder.

    Scripps Health and UT Health San Antonio purchase Oncora's software to improve physician documentation and enhance personalized cancer care

    Retrieved on: 
    Wednesday, April 13, 2022
    CEO, Adoption, Workflow, Clinical trial, Documentation, Scripps Health, Twitter, Software, Electronic health record, Research, Scripps, UT, Machine learning, Patient, EPIC, Efficiency, Health, EHR, Laika (EHR testing framework), UT Health East Texas - North Campus, University of Texas Health Science Center at San Antonio, Oncology, Cancer, Medical imaging

    PHILADELPHIA, April 13, 2022 /PRNewswire/ --Oncora Medical (Oncora) announced today that Scripps Health (Scripps) and UT Health San Antonio (UT Health), have both selected Oncora's advanced oncology patient care software to improve documentation efficiency and enhance personalized cancer care using structured data analytics and machine learning.

    Key Points: 
    • PHILADELPHIA, April 13, 2022 /PRNewswire/ --Oncora Medical (Oncora) announced today that Scripps Health (Scripps) and UT Health San Antonio (UT Health), have both selected Oncora's advanced oncology patient care software to improve documentation efficiency and enhance personalized cancer care using structured data analytics and machine learning.
    • The independent purchase and adoption of Oncora's software by these two leading cancer centers highlights the shared challenges and opportunities facing oncology providers today.
    • Oncora's clinical solution Oncora Patient Care helps oncologists produce high quality documentation while simultaneously capturing structured data throughout the entire patient journey.
    • Oncora builds EHR-integrated software to improve oncologists' workflow and documentation, while leveraging predictive models to enable personalized care.